Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Margolin

Showing results (281-290 of 406) with videos related to

Pageof 41
Sort By:
The American Journal of Psychiatry|January 19, 1999
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and costS K Avants, A Margolin, J L Sindelar, et al.
Cancer|March 15, 1994
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology TeamG Somlo, J H Doroshow, S J Forman, et al.
Brain : a Journal of Neurology|September 1, 1983
Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 yearsR Duara, R A Margolin, E A Robertson-Tchabo, et al.
World Journal of Gastroenterology|May 7, 2015
Non-physician endoscopists: A systematic reviewMaximilian Stephens, Luke F Hourigan, Mark Appleyard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Cancer|January 1, 1994
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancerG Somlo, J H Doroshow, S J Forman, et al.
Neurology|February 20, 1999
Increased CSF F2-isoprostane concentration in probable ADT J Montine, M F Beal, M E Cudkowicz, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Pageof 41

Showing results (281-290 of 406) with videos related to

Sort By:
Pageof 41
The American Journal of Psychiatry|January 19, 1999
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and costS K Avants, A Margolin, J L Sindelar, et al.
Cancer|March 15, 1994
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology TeamG Somlo, J H Doroshow, S J Forman, et al.
Brain : a Journal of Neurology|September 1, 1983
Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 yearsR Duara, R A Margolin, E A Robertson-Tchabo, et al.
World Journal of Gastroenterology|May 7, 2015
Non-physician endoscopists: A systematic reviewMaximilian Stephens, Luke F Hourigan, Mark Appleyard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Cancer|January 1, 1994
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancerG Somlo, J H Doroshow, S J Forman, et al.
Neurology|February 20, 1999
Increased CSF F2-isoprostane concentration in probable ADT J Montine, M F Beal, M E Cudkowicz, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Pageof 41